PROCEPT BioRobotics (NASDAQ:PRCT) Cut to “Equal Weight” at Wells Fargo & Company

Wells Fargo & Company downgraded shares of PROCEPT BioRobotics (NASDAQ:PRCT) from an overweight rating to an equal weight rating in a research note released on Wednesday, MarketBeat Ratings reports. The brokerage currently has $19.00 target price on the stock.

PRCT has been the subject of a number of other reports. Evercore began coverage on shares of PROCEPT BioRobotics in a report on Wednesday, June 24th. They set an “outperform” rating and a $30.00 price target for the company. Leerink Partners lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $31.00 to $29.00 in a report on Thursday, June 11th. UBS Group cut shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a research report on Tuesday, July 28th. Piper Sandler restated an “overweight” rating and set a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. Finally, Wall Street Zen raised PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.00.

PROCEPT BioRobotics Stock Up 1.9%

NASDAQ PRCT opened at $20.41 on Wednesday. The stock has a market cap of $1.16 billion, a PE ratio of -10.52 and a beta of 0.89. PROCEPT BioRobotics has a fifty-two week low of $16.67 and a fifty-two week high of $42.71. The business has a 50 day moving average price of $21.59 and a two-hundred day moving average price of $24.79. The company has a quick ratio of 5.51, a current ratio of 6.55 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $92.77 million. During the same quarter in the prior year, the business earned ($0.35) EPS. The company’s revenue for the quarter was up 19.3% on a year-over-year basis. As a group, sell-side analysts predict that PROCEPT BioRobotics will post -1.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PRCT. BlackRock Inc. acquired a new stake in shares of PROCEPT BioRobotics during the 2nd quarter valued at approximately $109,961,000. Prosight Management LP lifted its stake in PROCEPT BioRobotics by 1,692.4% during the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after purchasing an additional 1,303,009 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in PROCEPT BioRobotics by 58.6% in the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after purchasing an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. boosted its holdings in PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares during the period. Finally, UBS Group AG increased its stake in PROCEPT BioRobotics by 129.3% during the third quarter. UBS Group AG now owns 944,545 shares of the company’s stock valued at $33,711,000 after purchasing an additional 532,530 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: PROCEPT reported quarterly revenue of $94.5 million, ahead of the $92.8 million consensus estimate, with year-over-year growth of 19.3%. The revenue beat helped support the shares despite a modest earnings miss. PROCEPT gains after Q2 beat; Wells Fargo downgrades
• Neutral Sentiment: PROCEPT posted an adjusted loss of $0.47 per share, narrowly worse than the $0.46 consensus estimate. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.53 per share.
• Negative Sentiment: Wells Fargo downgraded PROCEPT to Equal Weight, adding pressure after the earnings report and signaling limited near-term upside in the firm’s view. Wells Fargo downgrades PROCEPT BioRobotics to Equal Weight
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased PRCT shares from February 28, 2024 through February 25, 2026. The allegations concern weaker-than-expected handpiece sales and excess customer inventory allegedly created by late-quarter bulk discounts. The reports reference an approximately 18% stock decline and larger losses from the class-period high. The allegations have not been proven. PROCEPT securities fraud class action
• Negative Sentiment: Investors have been notified that September 22, 2026 is the lead-plaintiff deadline, increasing visibility around potential litigation costs, disclosure concerns and reputational risk. PROCEPT shareholder alert and lead plaintiff deadline

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.